The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P. European Myeloma Network. Annals of Oncology 20(8):1303-17. FI: 5.647 (Q1) Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach Nieto WG, Almeida J, Romero A, Teodosio C, López A, Henriques AF, Sánchez ML, Jara-Acevedo M, Rasillo A, González M, Fernández-Navarro P, Vega T, Orfao A. Primary Health Care Group of Salamanca for the Study of MBL. Blood 114(1):33-7. FI: 10.555 (Q1) Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I-mutated chronic myeloid leukemia Sanchez-Guijo FM, Lopez-Jimenez J, Gonzalez T, Santamaría C, González M, Del Cañizo MC. Leukemia Research 33(6):e20-2. FI: 2.358 (Q3) A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia Hernández JA, Rodríguez AE, González M, Benito R, Fontanillo C, Sandoval V, Romero M, Martín-Núñez G, de Coca AG, Fisac R, Galende J, Recio I, Ortuño F, García JL, de las Rivas J, Gutiérrez NC, San Miguel JF, Hernández JM. Haematologica 94(3):364-71. FI: 6.416 (Q1) High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics Santamaría C , Chillón MC, García-Sanz R, Pérez C, Caballero D, Ramos F, García de Coca A, Alonso JM , Giraldo P, Bernal T , Queizán JA , Rodriguez JN , Fernández-Abellán P , Bárez A , Peñarrubia MJ , Vidriales MB, Balanzategui A , Sarasquete ME , Alcoceba M, Díaz-Mediavilla J , San Miguel JF and González M. Leukemia Research 33(12):1706-9. FI: 2.358 (Q3) Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, Gonzalez M. Blood 114(1):148-52. FI: 10.555 (Q1) Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas Robledo C, García JL, Caballero D, Conde E, Arranz R, Flores T, Grande C, Rodríguez J, García E, Sáez AI, González M, Gutiérrez NC, Piris MA, Hernández JM. Spanish Lymphoma/ Autologous Bone Marrow Transplant Study Group (GEL-TAMO). Cancer 115(16):3728-37. FI: 5.418 (Q1) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies Díez-Campelo M, Pérez-Simón JA, Pérez J, Alcoceba M, Richtmon J, Vidriales MB, San Miguel J. American Journal of Hematology 84(3):149-52. FI: 2.610 (Q2) Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial Ribera JM, Oriol A, González M, Vidriales MB, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, Martín-Reina V, Sarrá J, Parody R, de Oteyza JP, Bureo E, Bernal MT. Programa Español de Tratamiento en Hematología. Grupo Español de Trasplante Hemopoyético Groups. Haematologica 95(1):87-95. FI: 6.416 (Q1) Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia. A study of the Spanish PETHEMA group Cervantes F, López-Garrido P, Montero MI, Jonte F, Martínez J, Hernández-Boluda JC, Calbacho M, Sureda A, Pérez-Rus G, Nieto JB, Pérez-López C, Román-Gómez J, González M, Pereira A, Colomer D. Haematologica 95:1317-1324. FI: 6.416 (Q1)
|
